drugset
drugset / Trial / NCT07057726

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SSS39 Injection in Healthy Chinese Subjects

NCT07057726 ↗

Phase 1 Enrolling by invitation 48 enrolled Shenyang Sunshine Pharmaceutical Co., LTD.
RandomizedSingle-groupTriple-blindOther

Summary

To evaluate the safety, tolerability, and pharmacokinetics of SSS39 injection in healthy Chinese subjects

Timeline

Start
2024-10-09
Primary completion
2025-10
Completion
2025-10

Drugs

EvaluationDrugModalityDoseRoute
Subject SSS39 Unknown — Intravenous

Indications

No indication recorded.